Carla Boquimpani

1.4k total citations
29 papers, 241 citations indexed

About

Carla Boquimpani is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Carla Boquimpani has authored 29 papers receiving a total of 241 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 18 papers in Genetics and 8 papers in Rheumatology. Recurrent topics in Carla Boquimpani's work include Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Acute Lymphoblastic Leukemia research (8 papers). Carla Boquimpani is often cited by papers focused on Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Acute Lymphoblastic Leukemia research (8 papers). Carla Boquimpani collaborates with scholars based in Brazil, Germany and Japan. Carla Boquimpani's co-authors include Dong‐Wook Kim, Jeffrey H. Lipton, Noam Benyamini, Vasily Shuvaev, Anna Turkina, Tomasz Sacha, Naoto Takahashi, Timothy P. Hughes, Nelma Cristina D. Clementino and Jolanta Dengler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Carla Boquimpani

26 papers receiving 236 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carla Boquimpani Brazil	9	231	199	108	60	21	29	241
Vasily Shuvaev Russia	8	232 1.0×	211 1.1×	104 1.0×	54 0.9×	29 1.4×	54	255
Simone Claudiani United Kingdom	8	165 0.7×	136 0.7×	49 0.5×	45 0.8×	29 1.4×	31	209
Véronique Bédoucha Switzerland	5	327 1.4×	271 1.4×	163 1.5×	79 1.3×	36 1.7×	13	349
Jeffrey Skinner United States	6	188 0.8×	162 0.8×	94 0.9×	40 0.7×	18 0.9×	16	220
Nelma Cristina D. Clementino Brazil	8	293 1.3×	231 1.2×	132 1.2×	68 1.1×	39 1.9×	16	312
Katy Knight United Kingdom	7	179 0.8×	120 0.6×	85 0.8×	78 1.3×	13 0.6×	8	253
Jolanta Dengler Germany	6	165 0.7×	140 0.7×	83 0.8×	40 0.7×	20 1.0×	16	170
Nataliia Glushko Singapore	2	275 1.2×	217 1.1×	120 1.1×	77 1.3×	34 1.6×	2	327
Bronte A. Jamison Australia	5	307 1.3×	262 1.3×	148 1.4×	41 0.7×	41 2.0×	5	327
Alexandra L. Yeoman Australia	5	310 1.3×	263 1.3×	149 1.4×	42 0.7×	42 2.0×	6	330

Countries citing papers authored by Carla Boquimpani

Since Specialization

Citations

This map shows the geographic impact of Carla Boquimpani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carla Boquimpani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carla Boquimpani more than expected).

Fields of papers citing papers by Carla Boquimpani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carla Boquimpani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carla Boquimpani. The network helps show where Carla Boquimpani may publish in the future.

Co-authorship network of co-authors of Carla Boquimpani

This figure shows the co-authorship network connecting the top 25 collaborators of Carla Boquimpani. A scholar is included among the top collaborators of Carla Boquimpani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carla Boquimpani. Carla Boquimpani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lang, Fabian, Delphine Réa, Naoto Takahashi, et al.. (2025). Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey. Haematologica. 111(2). 597–608. 1 indexed citations

Biasoli, Irène, Nelson Castro, Fabı́ola Traina, et al.. (2023). Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry. SHILAP Revista de lepidopterología. 4(4). 1191–1195.

Réa, Delphine, Carla Boquimpani, Michael J. Mauro, et al.. (2023). Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 37(5). 1060–1067. 8 indexed citations

Atallah, Ehab, Michael J. Mauro, Andreas Hochhaus, et al.. (2023). Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. Journal of Cancer Research and Clinical Oncology. 149(9). 6247–6262. 12 indexed citations

Lang, Fabian, Delphine Réa, Naoto Takahashi, et al.. (2023). P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING. HemaSphere. 7(S3). e8318962–e8318962. 1 indexed citations

Réa, Delphine, Michael J. Mauro, Andreas Hochhaus, et al.. (2022). Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.. Journal of Clinical Oncology. 40(16_suppl). 7004–7004. 10 indexed citations

Hughes, Timothy P., Delphine Réa, Carla Boquimpani, et al.. (2022). Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study. Blood. 140(Supplement 1). 6757–6759. 3 indexed citations

Pavlovsky, Carolina, Kátia Bórgia Barbosa Pagnano, Michele Bianchini, et al.. (2021). Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Advances. 5(23). 4855–4863. 13 indexed citations

Boquimpani, Carla, et al.. (2020). Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management. Hematology Transfusion and Cell Therapy. 43(1). 50–57. 2 indexed citations

10.

Mauro, Michael J., Andreas Hochhaus, Carla Boquimpani, et al.. (2019). A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology. 37(15_suppl). TPS7070–TPS7070. 3 indexed citations

11.

Mauro, Michael J., Andreas Hochhaus, Carla Boquimpani, et al.. (2019). A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs. Clinical Lymphoma Myeloma & Leukemia. 19. S286–S287. 2 indexed citations

12.

Hughes, Timothy P., Carla Boquimpani, Naoto Takahashi, et al.. (2018). ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Clinical Lymphoma Myeloma & Leukemia. 18. S222–S222. 3 indexed citations

13.

Mahon, François‐Xavier, Carla Boquimpani, Naoto Takahashi, et al.. (2018). Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. Journal of Clinical Oncology. 36(15_suppl). 7003–7003. 5 indexed citations

14.

Mauro, Michael J., Fabian Lang, Dong‐Wook Kim, et al.. (2018). Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.. Journal of Clinical Oncology. 36(15_suppl). TPS7081–TPS7081. 1 indexed citations

15.

Abdo, André, Carla Boquimpani, Alisson L. Matsuo, et al.. (2018). Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment. Blood. 132(Supplement 1). 4760–4760. 1 indexed citations

16.

Mahon, François-Xavier, Carla Boquimpani, Dong‐Wook Kim, et al.. (2018). Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase. Annals of Internal Medicine. 168(7). 461–470. 95 indexed citations

17.

Mauro, Michael J., Carla Boquimpani, Yosuke Minami, et al.. (2017). Oral Asciminib (ABL001) vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Received ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): A Multicenter, Open-Label, Randomized, Phase 3 Study. Clinical Lymphoma Myeloma & Leukemia. 17. S315–S316. 3 indexed citations

18.

Mahon, François‐Xavier, Carla Boquimpani, Naoto Takahashi, et al.. (2016). Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood. 128(22). 1891–1891. 10 indexed citations

19.

Hughes, Timothy P., Carla Boquimpani, Naoto Takahashi, et al.. (2016). Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. Blood. 128(22). 792–792. 16 indexed citations

20.

Boquimpani, Carla, Rony Schaffel, Irène Biasoli, Israel Bendit, & Nelson Spector. (2014). Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Leukemia & lymphoma. 56(6). 1787–1792. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact